

Published on *Global Research Projects* (<https://globalprojects.ucsf.edu>)

Home > GSK\_201585: Phase III, randomized, multicenter, parallel-group, non inferiority, open-label study evaluating the efficacy, safety, & tolerability of switching to long-acting cabotegravir plus long acting rilpivirine from current INI,NNRTI, or PI-based ART

---

## **GSK\_201585: Phase III, randomized, multicenter, parallel-group, non inferiority, open-label study evaluating the efficacy, safety, & tolerability of switching to long-acting cabotegravir plus long acting rilpivirine from current INI,NNRTI, or PI-based ART**

© 2019 The Regents of the University of California

**Brought to you by:**



**Created by:**



---

**Source URL:** <https://globalprojects.ucsf.edu/project/gsk201585-phase-iii-randomized-multicenter-parallel-group-non-inferiority-open-label-study>